GI 270384X
Alternative Names: 270384Latest Information Update: 10 Jul 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class
- Mechanism of Action E-selectin inhibitors; Intercellular adhesion molecule-1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammatory bowel diseases
Most Recent Events
- 29 Nov 2004 Phase-II clinical trials in Inflammatory bowel disease in USA (unspecified route)
- 05 Dec 2003 Phase-I clinical trials in Inflammatory bowel disease in USA (unspecified route)
- 22 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline